Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the safety and efficacy of ARV-766 in men with metastatic castration-resistant prostate cancer.

Clinical Trial Description

The study will evaluate ARV-766 given once or twice daily to cohorts of patients in escalating doses. Each dose level will have safety assessed and if found safe and tolerable, the next cohort of patients will be enrolled at a higher dose level. Increasing dose levels will be evaluated until the highest safe dose is identified. Patients treated at lower doses may increase to the next higher dose level once it is determined to be safe, provided they have been on their current dose for 28 or more days and have no major side effects. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05067140
Study type Interventional
Source Arvinas Inc.
Contact Arvinas Androgen Receptor, Inc.
Phone 475-345-3374
Email [email protected]
Status Recruiting
Phase Phase 1
Start date September 2, 2021
Completion date June 27, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT03646162 - Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer Phase 2
Recruiting NCT03413995 - Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations Phase 2
Recruiting NCT05078151 - Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer N/A
Recruiting NCT03507595 - Evaluation of the Metastasis and Recurrence of Prostate Cancer
Completed NCT03362359 - Ga-68-PSMA-11 in High-risk Prostate Cancer Phase 1/Phase 2
Recruiting NCT04116775 - Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. Phase 2
Active, not recruiting NCT03223727 - Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223
Not yet recruiting NCT04983095 - Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer Phase 3
Recruiting NCT04086290 - National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients Phase 1/Phase 2
Recruiting NCT03129139 - A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelideā„¢ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04983628 - Molecular Profiling in Prostate Cancer
Active, not recruiting NCT03414437 - Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303)
Completed NCT02485691 - Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent Phase 4
Completed NCT03693742 - MSG Use With 18F-DCFPyL PET/CT Imaging N/A
Completed NCT01322490 - A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer Phase 3
Completed NCT03739684 - Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer Phase 3
Active, not recruiting NCT03295565 - Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel Phase 2/Phase 3
Recruiting NCT02961257 - Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel Phase 3
Recruiting NCT04848337 - Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer Phase 2